Hunter Syndrome

26 registered clinical trials studyying Hunter Syndrome.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitiv NCT06031259	Takeda	Phase 2 / Phase 3
Withdrawn	A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II) NCT05494593	Takeda	Phase 4
Active Not Recruiting	A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS NCT05422482	GC Biopharma Corp	Phase 1
Completed	A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India NCT05058391	Takeda	Phase 4
Terminated	MPS II Immunophenotyping NCT04976231	Duke University	—
Terminated	Biomarkers for Hunter Syndrome NCT01330277	CENTOGENE GmbH Rostock	—
Completed	An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta) NCT07344376	GC Biopharma Corp	Phase 3
Completed	Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701) NCT03582449	Shire	—
Completed	A Study of GC1111 in Hunter Syndrom Patients NCT03920540	Green Cross Corporation	Phase 3
Completed	Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age NCT02455622	Shire	Phase 4
Completed	Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Particip NCT02412787	Shire	Phase 2 / Phase 3
Active Not Recruiting	MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis NCT02171104	Masonic Cancer Center, University of Minnesota	Phase 2
Completed	Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunt NCT02055118	Shire	Phase 2 / Phase 3
Unknown	The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients NCT02044692	Green Cross Corporation	—
Completed	Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II) NCT01822184	Shire	—
Completed	Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome NCT01449240	Shire	—
Completed	Safety and Efficacy of Hunterase NCT01645189	Green Cross Corporation	Phase 3
Completed	An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conju NCT01506141	Takeda	Phase 1 / Phase 2
Completed	Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders NCT01043640	Masonic Cancer Center, University of Minnesota	Phase 2
Completed	A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery D NCT00920647	Shire	Phase 1 / Phase 2
Completed	Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervou NCT00937794	Shire	—
Completed	An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients NCT00882921	Shire	—
Completed	Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Ther NCT00607386	Shire	Phase 4
Completed	Hunter Outcome Survey (HOS) NCT03292887	Shire	—
Completed	Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idurs NCT00630747	Shire	Phase 2 / Phase 3
Available	Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome NCT05795361	Takeda	—